Nasal Drops

DEVICE2 trials

Sponsors

Rokote Laboratories Finland Oy, Peking University Third Hospital

Conditions

COVID19, Sars-Cov-2Chronic Rhinosinusitis (CRS)Olfactory Dysfunction

Phase 1

The Safety and Antibody Response of the Nasal COV2 Vaccine Against the SARS-CoV-2 Virus

CompletedNCT06851611

Rokote Laboratories Finland OyCOVID19, Sars-Cov-2

Start: 2025-01-21End: 2025-06-26Updated: 2025-12-08

Unknown Phase

Position-Directed Budesonide Nasal Drops for CRS-associated Olfactory Dysfunction

Not yet recruitingNCT07386873

Peking University Third HospitalChronic Rhinosinusitis (CRS), Olfactory Dysfunction

Start: 2026-09-25End: 2028-12-31Target: 78Updated: 2026-09-16